Phosphodiesterase-4 inhibitor, pharmaceutical composition comprising same, and use thereof

By developing compounds with PDE4 inhibitory activity, the problems of narrow therapeutic window and large side effects of PDE4 inhibitors in the prior art have been solved, which significantly alleviates the symptoms of psoriasis and atopic dermatitis, and improves skin sensitivity, achieving phosphate 2 Effective treatment of esterase 4-related diseases and the application of cosmetic ingredients.

WO2024239762A1PCT designated stage expired Publication Date: 2024-11-28SHANGHAI UNIV OF T C M +1
View PDF 7 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2024/080434
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-19
Filing Date
2024-03-07
Publication Date
2024-11-28

AI Technical Summary

Technical Problem

Existing PDE4 inhibitors have narrow therapeutic windows and persistent side effects in the treatment of psoriasis and atopic dermatitis, and lack effective treatments for skin-sensitive diseases.

Method used

A compound with PDE4 inhibitory activity and its pharmaceutical compositions are developed for the prevention and treatment of phosphodiesterase 4-related diseases, especially psoriasis and atopic dermatitis, and as a cosmetic ingredient to improve skin sensitivity. This compound increases the content of cAMP in cells by inhibiting PDE4 activity, significantly inhibits the secretion of the inflammatory factor TNF-α, and is used in preparation for treatment and cosmetics.

Benefits of technology

The compounds effectively inhibit PDE4 activity, significantly alleviate the symptoms of psoriasis and atopic dermatitis, improve skin sensitivity, have significant medicinal value and wide application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN2024080434_28112024_PF_FP_ABST
    Figure CN2024080434_28112024_PF_FP_ABST
Patent Text Reader

Abstract

The present invention relates to a phosphodiesterase-4 inhibitor, a pharmaceutical composition comprising same, and a use thereof. The phosphodiesterase-4 inhibitor has a structure as shown in formula I. Researches prove that the compound of formula I of the present application can effectively inhibit the activity of phosphodiesterase 4, can increase the accumulation of cAMP in cells, can significantly inhibit the secretion of inflammatory factors TNF-α in human peripheral blood mononuclear cells, is expected to be used as an active ingredient for preparing a drug for preventing and / or treating phosphodiesterase 4-related diseases or for preparing a cosmetic for improving skin sensitivity, and is particularly expected to be used for preparing a drug for preventing and / or treating psoriasis and atopic dermatitis. Therefore, the compound of the present application has significant medicinal value and wide application prospects.
Need to check novelty before this filing date? Find Prior Art

Description

Phosphodiesterase 4 inhibitor, pharmaceutical composition and use thereof Technical Field

[0001] The present invention belongs to the field of medical technology, and in particular relates to a phosphodiesterase 4 inhibitor, a pharmaceutical composition thereof and an application thereof. Background Art

[0002] Cyclic nucleotide phosphodiesterases (PDEs) are a superfamily of enzymes that catalyze the hydrolysis of cAMP and cGMP, encoded by 21 distinct genes. Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) are two second messengers that play important roles in cellular metabolism. PDEs can be divided into 11 distinct PDE families (PDE1–11) based on differences in substrate specificity and amino acid sequence. PDE4 is a highly cAMP-specific phosphodiesterase comprising four isoforms: PDE4A, PDE4B, PDE4C, and PDE4D. Studies have shown that inhibiting PDE4 can improve intracellular cAMP degradation, thereby activating PKA and affecting downstream pathways such as CREB / ATF-1 and NF-κB, leading to decreased synthesis of inflammatory cytokines and increased production of anti-inflammatory cytokines. PDE4 is widely distributed in various human tissues and cells, including the brain, kidney, cardiomyocytes, endothelial cells, and immune cells. Due to its organ-specific nature, PDE4 is involved in regulating cognitive function, promoting the expression of proinflammatory cytokines and chemokines by inflammatory cells (including peripheral blood mononuclear cells, macrophages, neutrophils, natural killer cells, basophils, and lymphocytes), and regulating vascular smooth muscle proliferation, vasodilation, and cardiac contraction. PDE4A, PDE4B, and PDE4D are also involved in the development of hematologic malignancies, central nervous system tumors, breast, lung, and prostate tumors. Animal models of Alzheimer's disease and stroke have confirmed that PDE4 is also a promising target for the treatment of central nervous system diseases. However, the narrow therapeutic window and persistent side effects such as nausea, vomiting, and diarrhea have severely hampered the clinical application of PDE4 inhibitors. Therefore, the development of new PDE4 inhibitors with a wider safety window and improved safety profile is of great significance.

[0003] Psoriasis is a multifactorial, intractable inflammatory skin disease characterized by scaly, red plaques that appear on frequently abraded parts of the body (such as the extensor parts of the limbs and scalp), accompanied by a variety of comorbidities, which seriously affect the patient's quality of life. The immunopathogenesis of psoriasis involves a variety of inflammatory mediators, including tumor necrosis factor (TNF-α), interleukins (IL-12, IL-17, IL-22, IL-23), and interferon (IFN)-γ. The treatment of psoriasis varies, from topical corticosteroids, retinoids, and calcipotriol, to oral conventional systemic therapy as a broad immunosuppressant, to biological therapy targeting specific cytokines. Among them, topical corticosteroids are the most commonly used, but their long-term side effects, such as skin atrophy and stretch marks, limit their use. In 2022, Zoryve (roflumilast) 0.3% cream was approved for the treatment of localized plaque psoriasis, proving that PDE4 inhibitors have great potential in the treatment of psoriasis. However, Zoryve still has the side effects of roflumilast, such as nausea, diarrhea, loss of appetite, and mild weight loss. Therefore, there is still a clinical need for drugs to treat psoriasis, and providing a highly effective and safe drug for the treatment of psoriasis is of great clinical significance.

[0004] Atopic dermatitis is a common allergic skin disease characterized by intense itching, dryness, erythema, and papules, affecting a wide range of individuals, including infants, adolescents, and adults. Persistent itching can cause severe sleep disturbances, interfering with daily activities and significantly reducing quality of life, placing a heavy burden on patients. Currently, the first-line treatment for atopic dermatitis remains steroid anti-inflammatory drugs, such as corticosteroids (e.g., prednisone, dexamethasone, and fludrocortisone). While these corticosteroids can alleviate atopic dermatitis symptoms, long-term use can lead to adverse reactions such as redness, thinning, atrophy, and growth retardation. Crisaborole, a topical anti-inflammatory drug, received FDA approval in 2016 and became available in the United States in early 2017 for the treatment of mild to moderate atopic dermatitis in adults and children aged two years and older, demonstrating the potential of PDE4 inhibitors in the treatment of atopic dermatitis.

[0005] Skin sensitivity refers to a skin condition characterized by subjective sensory symptoms induced by susceptibility to a variety of factors. This includes high skin reactivity, poor tolerance, and even susceptibility to allergies, such as those caused by cosmetic ingredients. Sensitive skin primarily occurs on the face, but also on the hands, feet, scalp, and other areas. The main characteristics of sensitive skin are drier, tighter, and more reddened skin compared to normal skin. Even the slightest irritation can cause itching, flaking, and even burning and stinging sensations. Inflammation is a key factor in sensitive skin. When skin is sensitive and uncomfortable, it is more susceptible to external irritants and allergens, leading to skin inflammation. Currently, there is no specific treatment for skin sensitivity. PDE4 plays a key role in various inflammatory skin conditions, making the development of PDE4 inhibitors to alleviate skin sensitivity crucial.

[0006] Summary of the Invention

[0007] In view of the above-mentioned problems existing in the prior art, the purpose of the present invention is to provide a compound with PDE4 inhibitory activity and its preparation method and application, so as to screen a new drug and / or cosmetic raw material for preventing and / or treating phosphodiesterase 4-related diseases and skin discomfort.

[0008] In a first aspect of the present invention, there is provided a compound represented by the following formula I, a stereoisomer, a precursor compound, a deuterated substance, or a pharmaceutically acceptable ester thereof:

[0009] In formula I, Z is O, NH or S;

[0010] R1 is selected from H, unsubstituted or halogen-substituted C1-C6 alkyl, unsubstituted or halogen-substituted C3-C6 cycloalkyl, and unsubstituted or halogen-substituted benzyl;

[0011] R2 and R3 are each independently selected from unsubstituted or halogen-substituted C1-C6 alkyl, unsubstituted or halogen-substituted C3-C6 cycloalkyl, and unsubstituted or halogen-substituted benzyl;

[0012] One of R6 and R7 is H, and the other is in, Indicates a single bond or a double bond;

[0013] R4 and R5 are each independently selected from

[0014] R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl,

[0015] In the above substituent options Indicates the key connection position,

[0016] Provided that the compound of formula I does not include compound

[0017] In a specific embodiment, the compound of formula I has the structure shown in the following formula I-1:

[0018] In formula I-1, each substituent is as defined above.

[0019] In a specific embodiment, in Formula I,

[0020] Z is O;

[0021] R1 is selected from H, C1-C6 alkyl;

[0022] R2 and R3 are each independently selected from C1 to C6 alkyl;

[0023] R6 is H, and R7 is in, Indicates a single bond or a double bond;

[0024] R4 and R5 are each independently selected from

[0025] R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl,

[0026] In the above substituent options Indicates the key connection location.

[0027] In a specific embodiment, in Formula I,

[0028] Z is O;

[0029] R1 is selected from H, C1-C6 alkyl;

[0030] R2 and R3 are each independently selected from C1 to C6 alkyl;

[0031] R6 is and R7 is H, wherein, Indicates a single bond or a double bond;

[0032] R4 and R5 are each independently selected from R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl,

[0033] In the above substituent options Indicates the key connection location.

[0034] In a specific embodiment, in Formula I,

[0035] Z is O;

[0036] R1 is H or methyl;

[0037] R2 and R3 are both methyl, or R2 and R3 are both ethyl;

[0038] R6 is H, and R7 is in, Indicates a single bond or a double bond;

[0039] R4 and R5 are each independently selected from

[0040] R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl,

[0041] In the above substituent options Indicates the key connection location.

[0042] In a specific embodiment, in Formula I,

[0043] Z is O;

[0044] R1 is H or methyl;

[0045] R2 and R3 are both methyl, or R2 and R3 are both ethyl;

[0046] R7 is H, and R6 is in, Indicates a single bond or a double bond;

[0047] R4 and R5 are each independently selected from

[0048] R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl,

[0049] In the above substituent options Indicates the key connection location.

[0050] In another aspect, the present invention provides a compound having the following structure:

[0051] In another aspect, the present invention provides a pharmaceutical composition comprising the compound of formula I, a deuterated substance thereof, or a pharmaceutically acceptable ester, and a pharmaceutically acceptable excipient.

[0052] In another aspect, the present invention provides use of a compound of the following formula I, a deuterated substance thereof, or a pharmaceutically acceptable ester thereof, or a pharmaceutical composition comprising the same, in the preparation of a medicament for treating a disease mediated by upregulation of phosphodiesterase 4:

[0053] In formula I, Z is O, NH or S;

[0054] R1 is selected from H, unsubstituted or halogen-substituted C1-C6 alkyl, unsubstituted or halogen-substituted C3-C6 cycloalkyl, and unsubstituted or halogen-substituted benzyl;

[0055] R2 and R3 are each independently selected from unsubstituted or halogen-substituted C1-C6 alkyl, unsubstituted or halogen-substituted C3-C6 cycloalkyl, and unsubstituted or halogen-substituted benzyl;

[0056] One of R6 and R7 is H, and the other is in, Indicates a single bond or a double bond;

[0057] R4 and R5 are each independently selected from Wherein, R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl, R 10 It is a C1~C6 alkyl group.

[0058] In the above substituent options Indicates the key connection location.

[0059] In a specific embodiment, the present invention provides the use of the following compound or a pharmaceutical composition comprising the same in the preparation of a medicament for treating a disease mediated by upregulation of phosphodiesterase 4, a PDE4 inhibitor, or a cosmetic for improving skin sensitivity:

[0060] In specific embodiments, the diseases include: diseases involving inflammation, such as asthma, COPD and pulmonary fibrosis, allergic disease states, such as atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, chronic glomerulonephritis, endotoxic shock, cystic fibrosis, arterial restenosis, atherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, diabetes, pneumoconiosis, toxic and allergic contact eczema, atopic eczema, seborrheic eczema, lichen simplex, pruritus of the anogenital area, alopecia areata, hypertrophic scars, discoid lupus erythematosus, systemic lupus erythematosus, follicular and generalized pyoderma, intrinsic or extrinsic acne, erythematosus, Acne, Beghet's disease, Henoch-Schonlein purpura nephritis, inflammatory bowel disease, leukemia, multiple sclerosis, gastrointestinal diseases, autoimmune diseases, etc.; cardiovascular diseases, such as arrhythmia, heart failure, idiopathic dilated cardiomyopathy, acute myocardial infarction, myocardial ischemia-reperfusion injury, and ischemic pulmonary hypertension; neurological and psychiatric disorders, such as Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), multiple system atrophy (MSA), schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, depression, stroke, as well as spinal cord injury, vascular dementia, and fragile X syndrome; malignant tumors including central nervous system tumors, hematological malignancies, lung cancer, liver cancer, oral cancer, breast cancer, colon cancer, stomach cancer, skin cancer, prostate cancer, head and neck cancer, bladder cancer, and pancreatic cancer.

[0061] In specific embodiments, the disease is psoriasis or atopic dermatitis.

[0062] In another aspect, the present invention provides a cosmetic comprising at least the compound of formula I, a deuterated substance thereof, or a pharmaceutically acceptable ester thereof as an active ingredient for improving skin sensitivity.

[0063] In a specific embodiment, the form of the cosmetic is not limited, and can be emulsion, oil, cream, etc.

[0064] In another aspect, the present invention provides a method for treating a phosphodiesterase 4-mediated disease in a subject, comprising administering to the subject a therapeutically effective amount of the compound of formula I, a deuterated form thereof, or a pharmaceutically acceptable ester thereof.

[0065] In another aspect, the present invention provides a method for treating psoriasis or atopic dermatitis in a subject, comprising administering to the subject a therapeutically effective amount of a compound of Formula I, a deuterated form thereof, or a pharmaceutically acceptable ester thereof, or administering a therapeutically effective amount of a pharmaceutical composition comprising a compound of Formula I, a deuterated form thereof, or a pharmaceutically acceptable ester thereof. Beneficial effects

[0066] The compounds of Formula I of the present application can effectively inhibit phosphodiesterase 4 activity, increase intracellular cAMP accumulation, and significantly inhibit the secretion of the inflammatory factor TNF-α in human peripheral blood mononuclear cells. Therefore, the compounds of Formula I are expected to be used as active ingredients in the preparation of drugs for the prevention and / or treatment of phosphodiesterase 4-related diseases, and are particularly expected to be used in the preparation of drugs for the prevention and / or treatment of psoriasis and atopic dermatitis. Therefore, they have significant pharmaceutical value and broad application prospects.

[0067] The general formula compound of the present application can also effectively improve skin sensitivity, and thus can be used to prepare cosmetics for improving skin sensitivity. BRIEF DESCRIPTION OF THE DRAWINGS

[0068] FIG1 shows the inhibition curve of compound 7b-1 in Test Example 1 on the PDE4D catalytic domain.

[0069] FIG2 shows the inhibition curve of compound 7b-1 in Test Example 2 on the secretion of inflammatory factor TNF-α in human PBMC cells.

[0070] Figure 3 shows the therapeutic effect of compound 7b-1 in Test Example 3 on imiquimod-stimulated psoriasis in mice. (A) Imiquimod-stimulated psoriasis lesion area and total severity index score in mice; (B) Erythema score in mouse back lesions; (C) Squama score in mouse back lesions; (D) Thickness score in mouse back lesions. Compared with the blank group, #P<0.05, ##P<0.01, ###P<0.001; compared with the drug matrix group, *P<0.05, **P<0.01, and ***P<0.001.

[0071] Figure 4 shows the therapeutic effect of compound 7b-1 in Test Example 4 on 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis in mice. (A) Scores of back lesions in mice during DNCB-induced skin allergy; (B) Squama scores in back lesions in mice; (C) Exfoliation scores in back lesions in mice; (D) Erythema scores in back lesions in mice; (compared with the blank group, #P<0.05, ##P<0.01, ###P<0.001; compared with the model group, *P<0.05, **P<0.01, and ***P<0.001). DETAILED DESCRIPTION

[0072] Hereinafter, the technical solution of the present application will be described in detail through specific embodiments so that those skilled in the art can better understand the present invention. However, the scope of protection of the present invention is not limited thereto, but includes all equivalent or alternative methods that can be made by those skilled in the art based on the understanding of the present invention.

[0073] the term

[0074] The term "C1-C6 alkyl" includes methyl, ethyl, propyl, butyl, pentyl and hexyl, preferably methyl or ethyl.

[0075] The term "C3-C6 cycloalkyl" refers to cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl.

[0076] The term "compound having PDE4 inhibitory activity" refers to a compound capable of inhibiting phosphodiesterase 4 and its isoforms.

[0077] The term "pharmaceutically acceptable" means that the substance does not have properties that would cause a reasonably prudent medical practitioner to avoid administering the substance to a patient, taking into account the disease or condition to be treated and the respective route of administration. For example, for injectables, it is generally required that such a substance be substantially sterile.

[0078] The term "stereoisomer" refers to isomers resulting from different spatial arrangements of atoms in a molecule, including conformational isomers, optical isomers, and the like.

[0079] The term "precursor compound" refers to a compound that is inactive in vitro but can be converted into the active ingredient of the present invention through metabolism or chemical reactions in the body, thereby exerting its pharmacological effect.

[0080] The drugs of the present invention can be administered to patients via various routes of administration, including but not limited to oral, transdermal, intramuscular, subcutaneous and intravenous injection.

[0081] The dosage form of the drug of the present invention is not limited, as long as it is a dosage form that can effectively allow the active ingredient to reach the body, including: tablets, sugar-coated tablets, film-coated tablets, enteric-coated tablets, capsules, hard capsules, soft capsules, oral liquids, lozenges, granules, granules, pills, powders, pastes, pills, suspensions, powders, solutions, injections, suppositories, ointments, plasters, creams, sprays, drops, patches, etc.; oral dosage forms are preferred, such as: capsules, tablets, oral liquids, granules, pills, powders, pills, pastes, etc.

[0082] In addition to the main active ingredient, the medicament and / or cosmetic of the present invention may also contain a small amount of secondary ingredients that do not affect the active ingredient and / or pharmaceutically acceptable carriers, as well as various necessary excipients for formulation. For example, when the medicament is in an oral dosage form, it may contain commonly used excipients such as binders, fillers, diluents, tableting agents, lubricants, disintegrants, colorants, flavorings, and wetting agents. The tablets may be coated if necessary. Suitable fillers include cellulose, mannitol, lactose, and other similar fillers; suitable disintegrants include starch, polyvinylpyrrolidone, and starch derivatives, such as sodium starch glycolate; suitable lubricants include, for example, magnesium stearate; and suitable pharmaceutically acceptable wetting agents include sodium lauryl sulfate.

[0083] The present invention also contemplates the use of pharmaceutically acceptable deuterated compounds or other non-radioactive substituted compounds of the compounds. Deuteration, the replacement of one or more or all hydrogen atoms in a drug's active molecular group with the isotope deuterium, is considered an excellent modification method because it is non-toxic and non-radioactive, approximately 6-9 times more stable than carbon-hydrogen bonds, and can block metabolic sites, extending the drug's half-life and thus reducing the therapeutic dose without affecting the drug's pharmacological activity.

[0084] As used herein, the term "ester" refers to a compound of Formula I of the present invention in which the hydroxyl group (if present) has been converted to the corresponding ester using, for example, an inorganic or organic anhydride, acid or acid chloride. The term "pharmaceutically acceptable ester" refers to an ester of a compound of Formula I described herein that is pharmacologically acceptable and substantially non-toxic to the subject to which it is administered. More specifically, these esters retain the biological effectiveness and properties of the compounds of Formula I described herein and act as prodrugs that, when administered in vivo, are metabolized or cleaved in a manner that produces the parent compound.

[0085] Examples of esters include, inter alia, the following groups: (1) carboxylates; (2) sulfonates, such as alkyl- or arylalkyl-sulfonates (e.g., methanesulfonate); (3) phosphonates; (4) monophosphates, diphosphates or triphosphates (including phosphoramidocyclic esters); (5) carbamates (e.g., N-methylcarbamate); (6) carbonates obtained by esterification of a hydroxyl group (e.g., methyl carbonate), the ester group including, for example, a straight-chain or branched alkyl group (e.g., ethyl, n-propyl, tert-butyl, n-butyl, methyl, propyl, isopropyl, butyl, isobutyl or pentyl), an alkoxyalkyl group (e.g., methoxymethyl, acetoxymethyl and 2,2-dimethylpropionyloxymethyl), an aralkyl group (e.g., benzyl), an aryloxyalkyl group (e.g., phenoxymethyl), an aryl group (e.g., phenyl optionally substituted, for example, by halogen, C1-4 alkyl or C1-4 alkoxy or amino).

[0086] The compounds of Formula I described herein can be esterified by various conventional methods, including reacting an appropriate anhydride, carboxylic acid, or acid chloride with an alcohol group of the compounds described herein. For example, an appropriate anhydride can be reacted with an alcohol in the presence of a base such as 1,8-bis[dimethylamino]naphthalene or N,N-dimethylaminopyridine to promote acylation. In addition, a suitable carboxylic acid can be reacted with an alcohol in the presence of a dehydrating agent such as dicyclohexylcarbodiimide, 1-[3-dimethylaminopropyl]-3-ethylcarbodiimide, or other water-soluble dehydrating agent for driving the reaction by removing water, and optionally an acylation catalyst. Esterification can also be carried out using an appropriate carboxylic acid. Reactions of an acid chloride with an alcohol can also be carried out. When the compounds described herein contain numerous free hydroxyl groups, those groups that are not converted to prodrug functional groups can be protected (e.g., using tert-butyl-dimethylsilyl groups) and then deprotected. Furthermore, enzymatic methods can be used to selectively phosphorylate or dephosphorylate alcohol functional groups. Those skilled in the art will readily appreciate how to successfully implement these and other known alcohol esterification methods.

[0087] The present invention will be further described below with reference to the accompanying drawings and specific embodiments.

[0088] The preparation process of each specific compound in the following examples is shown in the following reaction scheme:

[0089] In the above reaction formula, R1 is methyl or ethyl.

[0090] Example 1: Preparation of Compound 7a

[0091] Preparation of Intermediate 2a: 1a (10 g, 60.24 mmol) and malonic acid (8.77 g, 84.34 mmol) were added to a reaction flask. Toluene (180 mL) was added to dissolve the mixture. Pyridine (36 mL) and piperidine (6 mL) were then added, and a water separator was installed. The mixture was refluxed (110°C) for 6 h, resulting in the precipitation of a large amount of white solid. The reaction was terminated by filtering the reaction system to obtain an off-white solid, Compound 2b (13.38 g), which was used directly in the next step.

[0092] Preparation of intermediate 3a: Dissolve 2a (15 g, 77.3 mmol) in anhydrous methanol (150 mL). Slowly add concentrated sulfuric acid (4.5 mL) dropwise. Stir at reflux (70°C) for 4 hours to terminate the reaction. Add ethyl acetate (400 mL) and water (100 mL) to dilute the reaction solution. Extract with ethyl acetate, and wash the organic phase with saturated sodium bicarbonate and saturated sodium chloride. Combine the organic phases, dry over anhydrous sodium sulfate, filter, and concentrate to obtain a yellow oil (15.1 g) for the next reaction.

[0093] Preparation of Compound 4a: To a reaction flask containing Compound 3a, add anhydrous dichloromethane (150 mL) and dissolve thoroughly. Then, add silver oxide (8.92 g, 38.5 mmol). Under nitrogen, wrap the flask with aluminum foil and stir at room temperature for 24 hours before terminating the reaction. The reaction mixture is filtered through diatomaceous earth, concentrated, and separated by column chromatography to afford Compound 4a (4.4 g, 28% yield over two steps) as a white solid.

[0094] The H NMR spectrum data of 4a are as follows:

[0095] 1 H NMR(500MHz,DMSO-d6)δ9.16(s,1H),7.63(d,J=15.9Hz,1H),7.38(s,1H),7.28(s,1H),7.00(d,J=2.0Hz,1H),6.81(dd,J=8.2,2.0Hz,1H),6. 76(d,J=8.0Hz,1H),6.56(d,J=15.9Hz,1H),5.91(d,J=7.8Hz,1H),4.54(d,J=7.8Hz,1H),3.84(s,3H),3.76(s,3H),3.75(s,3H),3.72(s,3H).

[0096] Preparation of Compound 5a: Compound 4a (4.3 g, 10.4 mmol) was added to a reaction flask, and anhydrous acetone (100 mL) was added to dissolve the solid. Potassium carbonate (14.4 g, 104.3 mmol) and dimethyl sulfate (9.89 mL, 104.3 mmol) were added, and the reaction was stirred at reflux (60°C) for 4 h before termination. Methanol (20 mL) was added to the reaction solution, and after sonication, a large amount of white solid precipitated. The solution was transferred to a refrigerator overnight and filtered to obtain Compound 5a (2.7 g, 61% yield) as a white solid.

[0097] The H NMR spectrum data of 5a are as follows:

[0098] 1 H NMR (500MHz, DMSO-d6) δ7.63(d,J=16.0Hz,1H),7.39(d,J=1.5Hz,1H),7.28(t,J=1.3Hz,1H),7.03(d,J=1.8Hz,1H),6. 94(m,2H),6.56(d,J=15.9Hz,1H),5.96(d,J=7.8Hz,1H),4.55(d,J=7.8Hz,1H),3.85(s,3H),3.75(m,9H),3.71(s,3H).

[0099] Preparation of Compound 6a: 5a (2 g, 4.67 mmol) was added to a reaction flask and dissolved in ethyl acetate (25 mL). Palladium on carbon (200 mg, 10 wt%) was added and hydrogen was introduced. The reaction was allowed to react at room temperature for 3 h. The reaction mixture was filtered through celite and concentrated to obtain Compound 6a as a pale yellow oil, which was used for the next reaction.

[0100] The H NMR spectrum data of 6a are as follows:

[0101] 1 H NMR (500MHz, DMSO-d6) δ7.02(d,J=2.0Hz,1H),6.95(d,J=8.3Hz,1H),6.92(dd,J=8.3,1.9Hz,1H),6.85(d,J=1.6Hz,1H),6.76(t,J= 1.3Hz,1H),5.87(d,J=8.1Hz,1H),4.46(d,J=8.0Hz,1H),3.78(s,3H),3.75(m,9H),3.60(s,3H),2.81(t,J=7.6Hz,2H),2.65(m,2H).

[0102] Preparation of Compound 7a: Lithium aluminum tetrahydride (1.57 g, 41.4 mmol) was added to a dried three-necked flask. Under nitrogen, the mixture was placed in an ice bath and dissolved in anhydrous tetrahydrofuran (20 mL). Compound 6a was dissolved in anhydrous tetrahydrofuran (20 mL) and slowly added to the reaction system. The reaction was allowed to react at room temperature for 2 h before termination. Water (1.57 mL) was slowly added dropwise in an ice bath to quench the reaction. The pH was adjusted to acidic with 1 M HCl, and the mixture was extracted with ethyl acetate. The organic phases were washed with saturated sodium bicarbonate and saturated sodium chloride. The combined organic phases were dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to afford Compound 7a (1.1 g, 63% yield over two steps) as a colorless oil.

[0103] The H NMR spectrum data of 7a are as follows:

[0104] 1 H NMR (500MHz, DMSO-d6) δ6.94(d,J=8.9Hz,2H),6.89(d,J=8.2Hz,1H),6.70(s,2H),5.78(s,0H),5.46(d,J=6.7Hz,1H),5.04(t,J= 5.3Hz, 1H), 4.47 (t, J = 5.1Hz, 1H), 3.78 (s, 3H), 3.74 (d, J = 2.9Hz, 6H), 3.63 (m, 2H), 3.42 (q, J = 6.1Hz, 3H), 1.70 (p, J = 7.1Hz, 2H).

[0105] Example 2: Preparation of Compounds 7a-1 and 7a-2

[0106] Preparation of compounds 7a-1 and 7a-2: Compound 7a was injected into a DAICEL CHIRALPAK AD-H column using petroleum ether-ethanol (80:20) as the mobile phase at a flow rate of 0.8 mL / min, a column temperature of 25°C, and UV detection at a wavelength of 210 nm to obtain enantiomers 7a-1 (450 mg, purity: 99.2%) and 7a-2 (510 mg, purity: 99.8%).

[0107] Example 3: Preparation of Compound 9a

[0108] Preparation of Compound 8a: To a round-bottom flask containing Compound 5a (400 mg, 0.93 mmol) was added lithium hydroxide monohydrate (153 mg, 3.74 mmol) dissolved in tetrahydrofuran:methanol:water (4:2:2 mL). The reaction was allowed to react at room temperature for 4 hours. The reaction solution was concentrated, the pH adjusted to acidic with 1M HCl, and extracted with ethyl acetate. The combined organic phases were washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, concentrated, and isolated by column chromatography to afford 8a (251 mg, 68%) as a white solid.

[0109] The H NMR spectrum data of 8a are as follows:

[0110] 1 H NMR(500MHz,DMSO-d6)δ12.69(s,2H),7.55(d,J=15.8Hz,1H),7.34(s,1H),7.24(s,1H),7.01(s,1H),6.93(q, J=8.4Hz,2H),6.42(d,J=15.8Hz,1H),5.94(d,J=7.6Hz,1H),4.41(d,J=7.6Hz,1H),3.84(s,3H),3.74(s,6H).

[0111] Preparation of compound 9a: To a round-bottom flask containing 8a (230 mg, 0.58 mmol) was added dioxane (5 mL) to dissolve the reactants. Di-tert-butyl dicarbonate (0.396 mL, 1.73 mmol), pyridine (0.138 mL, 1.73 mmol), and ammonium bicarbonate (136 mg, 1.73 mmol) were then added. The reaction was stirred overnight at room temperature and terminated. The reaction mixture was concentrated and purified by column chromatography to afford compound 9a (133 mg, 58%) as a white solid.

[0112] The tested H NMR spectrum data of 9a are as follows:

[0113] 1 H NMR (500MHz, DMSO-d6) δ7.82(d,J=2.4Hz,1H),7.44(s,1H),7.37(m,2H),7.14(d,J=1.7Hz,1H),7.09(s,1H),6.98(m,2H),6.93(d,J=2.0Hz ,1H),6.87(dd,J=8.3,2.0Hz,1H),6.47(d,J=15.8Hz,1H),5.95(d,J=7.9Hz,1H),4.23(d,J=7.9Hz,1H),3.84(s,3H),3.75(d,J=3.6Hz,6H).

[0114] Example 4: Preparation of Compound 10a

[0115] Preparation of Compound 10a: Compound 7a (100 mg, 0.27 mmol) was added to a reaction flask and dissolved in dichloromethane. Triethylamine (167 μL, 1.20 mmol) and methanesulfonyl chloride (50 μL, 0.64 mmol) were added under an ice bath, protected by nitrogen, and allowed to react at room temperature for 2 hours. The reaction solution was adjusted to an acidic pH with 1 M HCl, extracted three times with dichloromethane, washed with saturated sodium chloride, dried over anhydrous sodium sulfate, concentrated, and separated by column chromatography to obtain Compound 10a (82 mg, 63%).

[0116] The H NMR spectrum data of 10a are as follows:

[0117] 1 H NMR (500MHz, DMSO-d6) δ6.97(m,2H),6.90(d,J=8.3Hz,1H),6.81(s,2H),5.51(d,J=7.1Hz,1H),4.53(dd,J=10.2,4.9Hz,1H),4.47(dd,J=10.2 ,6.9Hz,1H),4.20(t,J=6.2Hz,2H),3.79(s,3H),3.74(d,J=3.0Hz,6H),3.20(s,3H),3.18(s,3H),2.62(t,J=7.7Hz,2H),1.96(p,J=6.7Hz,2H).

[0118] Example 5: Preparation of Compound 11a

[0119] Trichloroacetyl isocyanate (22.6 mg, 0.12 mmol) was added to compound 7a (20 mg, 0.05 mmol) in dichloromethane (3 mL) and the mixture was cooled on ice. After 3 hours, TLC confirmed the complete reaction. After concentration, the mixture was dissolved in methanol (3 mL) and anhydrous potassium carbonate (1.38 mg, 0.01 mmol) was added, followed by stirring overnight. Post-treatment: The reaction mixture was concentrated, extracted with dichloromethane and water, washed with saturated ammonium chloride and saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, and separated by column chromatography to yield compound 11-a (9 mg, 39%).

[0120] The tested H NMR spectrum data of 11a are as follows:

[0121] 1 H NMR (400MHz, DMSO-d6) δ6.91(m,3H),6.74(s,2H),6.47(s,4H),5.42(d,J=7.2Hz,1H),4.19(p,J=10.2,9. 1Hz,2H),3.97(m,3H),3.78(s,3H),3.74(s,6H),3.68-3.57(m,1H),2.67-2.53(m,3H),1.90-1.74(m,2H).

[0122] Example 6: Preparation of Compound 12a

[0123] Preparation of compound 12a: 8a (50 mg, 0.125 mmol) and N,N,N′,N′-tetramethyl-O-(7-azabenzotriazol-1-yl)uronium hexafluorophosphate (104.5 mg, 0.215 mmol) were added to a reaction flask and dissolved in dichloromethane. Dimethylamine (17.2 μL, 0.25 mmol), triethylamine (69.3 μL, 0.5 mmol), and N,N-dimethylformamide (2 drops) were added. The reaction was allowed to react at room temperature for 3 hours under a nitrogen atmosphere. The reaction mixture was acidified with 1 M HCl and extracted with dichloromethane. The organic phase was washed three times with water and saturated sodium chloride, dried over anhydrous sodium sulfate, and separated by column chromatography to afford 12a (37 mg, 65%) as an off-white solid.

[0124] The tested H NMR spectrum data of 12a are as follows:

[0125] 1H NMR (500MHz, DMSO-d6) δ7.45(d,J=15.3Hz,1H),7.34(s,1H),7.06(m,3H),6.94(t,J=6.5Hz,2H),5.93(d,J=8 .5Hz,1H),4.89(d,J=8.5Hz,1H),3.85(s,3H),3.75(s,5H),3.16(s,3H),3.12(s,3H),2.92(d,J=4.1Hz,6H).

[0126] Example 7: Preparation of Compound 7b

[0127] Preparation of compound 2b: The method is the same as that of 2a.

[0128] Preparation of compound 3b: The method was the same as that of 3a. After cooling, the product was recrystallized to give an off-white solid compound 3b (9.2 g, two-step yield 69%).

[0129] The H NMR spectrum data of 3b are as follows:

[0130] 1 H NMR(500MHz,DMSO-d6)δ9.52(s,1H),7.55(d,J=15.9Hz,1H),7.29(d,J=2.0Hz,1H),7.11(dd,J=8.2,2.0Hz,1 H), 6.81 (d, J = 8.2Hz, 1H), 6.45 (d, J = 15.9Hz, 1H), 4.07 (q, J = 7.0Hz, 2H), 3.69 (s, 3H), 1.33 (t, J = 7.0Hz, 3H).

[0131] Preparation of compound 4b: The method was the same as that of compound 4a to give off-white solid compound 4b (2.03 g, 23%).

[0132] The H NMR spectrum data of 4b are as follows:

[0133] 1H NMR(500MHz,DMSO-d6)δ9.12(s,1H),7.63(d,J=15.9Hz,1H),7.33(m,2H),7.00(d,J=2.0Hz,1H),6.82(m,2H),6.56(d,J=16.0Hz,1H),5 .90(d,J=7.8Hz,1H),4.55(d,J=7.8Hz,1H),4.13(qd,J=7.0,4.6Hz,2H),4.01(m,2H),3.75(s,3H),3.72(s,3H),1.32(t,J=6.9Hz,6H).

[0134] Preparation of compound 5b: The method was the same as that of compound 5a to give white solid compound 5b (165 mg, 82%).

[0135] The H NMR spectrum data of 5b are as follows:

[0136] 1 H NMR (500MHz, DMSO-d6) δ7.62(d,J=15.9Hz,1H),7.37(s,1H),7.27(s,1H),7.02(s,1H),6.95(t,J=6.1Hz,2H),6.55(d,J=15.9Hz,1 H),5.93(d,J=7.8Hz,1H),4.54(d,J=7.8Hz,1H),4.15(m,J=7.3,6.6Hz,2H),3.99(m,2H),3.74(m,9H),1.30(td,J=6.9,4.0Hz,6H).

[0137] Preparation of compound 6b: The method was the same as that of compound 6a to give off-white solid compound 6b (127 mg, 82%).

[0138] The nuclear magnetic resonance hydrogen spectrum data of 6b tested are as follows:

[0139] 1H NMR (500MHz, DMSO-d6) δ6.99(d,J=1.9Hz,1H),6.93(m,2H),6.81(d,J=1.8Hz,1H),6.74(s,1H),5.83(d,J=8.1Hz,1H),4.43(d,J=8.1Hz, 1H),4.02(m,3H),3.75(s,3H),3.72(s,3H),3.58(s,3H),2.78(t,J=7.6Hz,2H),2.60(td,J=8.0,7.6,4.9Hz,2H),1.29(q,J=6.9Hz,6H).

[0140] Preparation of compound 7b: The method was the same as that of compound 7a to give compound 7b (97 mg, 95%) as a pale yellow oil.

[0141] The H NMR spectrum data of 7b are as follows:

[0142] 1 H NMR(500MHz,DMSO-d6)δ6.93(dd,J=5.2,3.1Hz,2H),6.87(dd,J=8.3,2.0Hz,1H),6.67(d,J=7 .7Hz,2H),5.76(s,1H),5.43(d,J=6.7Hz,1H),5.01(t,J=5.3Hz,1H),4.44(t,J=5.1Hz,1H),4. 13-3.93(m,4H),3.74(s,3H),3.69(dt,J=10.6,5.3Hz,1H),3.60(dt,J=10.7,6.4Hz,1H),3.4 0(p,J=5.7Hz,3H),2.52(d,J=8.5Hz,2H),1.68(dq,J=13.2,6.8Hz,2H),1.30(q,J=6.7Hz,6H).

[0143] Example 8: Preparation of Compounds 7b-1 and 7b-2

[0144] Preparation of compounds 7b-1 and 7b-2: The method was the same as that of compounds 7a-1 and 7a-2 to obtain enantiomers 7b-1 (1 g, purity: 96%) and 7b-2 (0.94 g, purity: 99%).

[0145] Example 9: Preparation of Compound 9b

[0146] Preparation of compound 8b: The method was the same as that of 8a to give compound 8b (222 mg, 61%) as a white solid.

[0147] The tested H NMR spectrum data of 8b are as follows:

[0148] 1 H NMR (500MHz, DMSO-d6) δ12.69(s,2H),7.56(d,J=15.9Hz,1H),7.33(d,J=1.7Hz,1H),7.2 5(d,J=1.3Hz,1H),7.02(d,J=1.9Hz,1H),6.97(d,J=8.4Hz,1H),6.94(dd,J=8.3,1.9Hz,1 H),6.42(d,J=15.9Hz,1H),5.94(d,J=7.7Hz,1H),4.41(d,J=7.6Hz,1H),4.14(qd,J=7.0, 4.5Hz, 2H), 4.01 (dtt, J=16.5, 9.6, 7.0Hz, 2H), 3.77 (s, 3H), 1.32 (td, J=7.0, 5.2Hz, 6H).

[0149] Preparation of compound 9b: The method was the same as that of 9a to give an off-white compound 9b (20 mg, 40%).

[0150] The tested H NMR spectrum data of 9b are as follows:

[0151] 1 H NMR(500MHz,DMSO-d6)δ7.82(d,J=2.5Hz,1H),7.44(s,1H),7.35(m,2H),7.12(d,J=1.6 Hz,1H),7.08(s,1H),7.00(s,1H),6.97(d,J=8.3Hz,1H),6.92(d,J=2.0Hz,1H),6.87(dd ,J=8.3,2.0Hz,1H),6.46(d,J=15.7Hz,1H),5.92(d,J=7.9Hz,1H),4.22(d,J=7.9Hz,1H) ,4.11(qd,J=6.9,4.7Hz,2H),3.99(q,J=7.0Hz,2H),3.75(s,3H),1.31(q,J=6.8Hz,7H).

[0152] Example 10: Preparation of Compound 10b

[0153] Preparation of compound 10b: The method was the same as that of compound 10a to give compound 10b (37 mg, 53%) as a pale yellow oil.

[0154] The tested H NMR spectrum data of 10b are as follows:

[0155] 1 H NMR (500MHz, DMSO-d6) δ6.97(m,2H),6.90(dd,J=8.3,2.0Hz,1H),6.82-6.76(m,2H),5.49(d,J=7. 0Hz,1H),4.52(dd,J=10.1,4.9Hz,1H),4.46(dd,J=10.1,7.0Hz,1H),4.20(t,J=6.3Hz,2H),4.07(d ddd,J=16.7,9.8,7.0,2.7Hz,2H),3.99(qd,J=6.9,1.8Hz,2H),3.80(q,J=6.5Hz,1H),3.31(s,10H ),3.19(s,3H),3.17(s,3H),2.61(dd,J=8.9,6.5Hz,2H),1.95(m,2H),1.30(td,J=7.0,3.5Hz,6H).

[0156] Example 11: Preparation of Compound 12b

[0157] Preparation of compound 12b: The method was the same as that of compound 12a to give off-white solid compound 12b (46 mg, 40%).

[0158] The tested H NMR spectrum data of 12b are as follows:

[0159] 1 H NMR (500MHz, DMSO-d6) δ7.43(d,J=15.2Hz,1H),7.32(d,J=1.5Hz,1H),7.04(m,3H),6.94(m,2H),5.90(d,J=8.4Hz,1H),4.88(d ,J=8.5Hz,1H),4.15(m,2H),4.00(m,2H),3.75(s,3H),3.16(s,3H),3.11(s,3H),2.91(d,J=6.0Hz,6H),1.31(q,J=6.8Hz,7H).

[0160] Example 12: Preparation of Compound 16

[0161] Preparation of Compound 13: Salvianolic acid B (60% purity, 10 g, 13.9 mmol) was added to a reaction flask and dissolved in anhydrous acetone (150 mL). Potassium carbonate (38.4 g, 278 mmol) and dimethyl sulfate (39.5 mL, 417 mmol) were then added sequentially. The reaction was refluxed (60°C) for 5 h before termination. The reaction mixture was filtered through celite, concentrated, and separated by column chromatography to afford Compound 13 (2.52 g, 36%) as a yellow solid.

[0162] The nuclear magnetic resonance hydrogen spectrum data of test 13 are as follows:

[0163] 1 H NMR(500MHz,DMSO-d6)δ7.55(d,J=15.9Hz,1H),7.42(d,J=8.6Hz,1H),7.07(d,J=8 .6Hz,1H),6.93(m,2H),6.82(m,4H),6.71(d,J=8.2Hz,1H),6.66(d,J=2.0Hz,1H), 6.51(dd,J=8.2,2.0Hz,1H),6.41(d,J=15.9Hz,1H),5.84(d,J=5.6Hz,1H),5.22(m ,2H),4.70(d,J=5.6Hz,1H),3.88(s,3H),3.73(m,15H),3.60(m,9H),3.01(m,3H).

[0164] Preparation of Intermediate 14: Compound 13 (2.5 g, 2.96 mmol) was added to a reaction flask and dissolved in dichloromethane (30 mL). Sodium methoxide (0.64 g, 11.84 mmol, dissolved in 19.7 mL of methanol to a 0.6 N concentration) was slowly added dropwise in an ice bath. The mixture was stirred at room temperature for 2.5 h. TLC confirmed the complete reaction. The pH was adjusted to acidic by adding 1 M HCl in an ice bath. The mixture was extracted with ethyl acetate. The combined organic phases were washed with saturated sodium chloride, dried over anhydrous sodium sulfate, filtered, concentrated, and separated by column chromatography to afford Compound 14 (0.9 g, 71%) as a yellow oil.

[0165] The nuclear magnetic resonance hydrogen spectrum data of test 14 are as follows:

[0166] 1H NMR (500MHz, DMSO-d6) δ7.62(d,J=15.9Hz,1H),7.42(d,J=8.5Hz,1H),7.04(m,2H),6.92(m,3H),6.46(d,J=15.9Hz, 1H),5.95(d,J=5.7Hz,1H),4.75(d,J=5.7Hz,1H),3.87(s,3H),3.76(s,3H),3.75(s,4H),3.71(s,3H),3.70(s,3H).

[0167] Preparation of compound 15: The method was the same as that of 6a to give compound 15 as a pale yellow oil (136 mg, 71%).

[0168] The nuclear magnetic resonance hydrogen spectrum data of test 15 are as follows:

[0169] 1 HNMR(500MHz,DMSO-d6)δ6.93(ddd,J=33.5,16.6,10.1Hz,4H),6.73(d,J=8.3Hz,1H),5.86(d, J=5.8Hz,1H),4.48(d,J=5.8Hz,1H),3.76(dt,J=19.0,15.5Hz,14H),3.55(s,3H),2.69(m,2H).

[0170] Preparation of compound 16: The method was the same as that of compound 7a to give compound 16 (60 mg, 51%) as a pale yellow oil.

[0171] The nuclear magnetic resonance hydrogen spectrum data of 16 are as follows:

[0172] 1 H NMR (500MHz, DMSO-d6) δ6.90(d,J=8.3Hz,1H),6.85(d,J=2.0Hz,1H),6.79(td,J=5.5,2.8Hz,2H),6.62(d,J=8.3Hz,1H),5.64(d,J=2.8Hz, 1H),5.13(t,J=5.2Hz,2H),4.45(t,J=5.1Hz,1H),3.75(s,4H),3.71(s,3H),3.70(s,3H),3.42(m,4H),2.51(m,9H),1.64(p,J=6.9Hz,2H).

[0173] Example 13: Preparation of Compound 18

[0174] Preparation of compound 17: The method was the same as that for compound 8a, and the crude product was used directly in the next step.

[0175] Preparation of compound 18: The method was the same as that of compound 9a to give off-white solid compound 18 (27 mg, two-step yield 27%).

[0176] Preparation Example 1: Preparation of Compound 7b Lotion

[0177] The components of phase AD are shown in Table 1 below, and a lotion is prepared as follows.

[0178] 1) Pre-disperse sodium hyaluronate evenly, add other ingredients in phase A, stir evenly, and heat to 80-85°C.

[0179] 2) Add all ingredients from Phase B and raise the temperature to 80-85°C. Add Phase B to Phase A (stirring) and homogenize at medium-high speed (10,000-12,000 rpm) for 5 minutes.

[0180] 3) Cool to 50°C, add phase C, and homogenize at medium-low speed (7000-8000 rpm) for 3 minutes.

[0181] 4) Cool to 45°C and add phase D. The solid powder needs to be pre-dissolved.

[0182] 5) Stop.

[0183] Table 1 Component formula of lotion

[0184] Preparation Example 2: A moisturizing lotion was prepared in the same manner as in Preparation Example 1, except that the raw materials of the moisturizing lotion were composed of the following (by weight percentage): 0.05% disodium EDTA, 2% glycerin, 0.5% panthenol, 2% butylene glycol, 0.03% hyaluronic acid, 0.01% sodium hyaluronate, 2% EMULIUM MELLIFERA raw material, 2% squalane, 2% caprylic / capric triglyceride, 2% dimethicone, 1% compound 7b, 0.9% Simulgel 305 raw material, 0.8% SPECTRASTAR PHL raw material, 1% NACARE Cerasome III (ceramide), 6% raw material, and the balance being water.

[0185] Preparation Example 3: A lotion was prepared in the same manner as in Preparation Example 1, except that the raw materials of the lotion were composed of the following (by weight percentage): 0.05% disodium EDTA, 2% glycerin, 0.5% panthenol, 2% butylene glycol, 0.03% hyaluronic acid, 0.01% sodium hyaluronate, 2% EMULIUM MELLIFERA raw material, 2% squalane, 2% caprylic / capric triglyceride, 2% dimethicone, 0.5% compound 7b, 0.9% Simulgel 305 raw material, 0.8% SPECTRASTAR PHL raw material, 1% NACARE Cerasome III (ceramide), 6% raw material, and the balance being water.

[0186] Comparative Preparation Example 1: A moisturizing lotion used as a comparative example was prepared in the same manner as Preparation Example 1 except that compound 7b was not included.

[0187] Test Example 1: Determination of the inhibitory activity of compounds against PDE4

[0188] The phosphodiesterase proximity assay (SPA) was used to determine the inhibitory activity of the compounds on PDE4. 3 H]-cAMP hydrolysis products [ 3 The effect of compounds on PDE4 hydrolysis activity is identified by the luminescence emitted by [H]-AMP bound to scintillation beads under the chelation of metal ions. The entire enzymatic reaction volume is 125 μL, and a protein solution with a concentration of 0.01-0.06 ng / μL is prepared in assay buffer (50 mM Tris pH 7.5, 8.3 mM MgCl2, 1.7 mM EGTA).

[0189] Specific experimental steps: Use SPA reaction buffer to prepare protein solution (working concentration is 0.01-0.06ng / μL) and compound of corresponding concentration. During the test, the reaction system of each well is 125μL, and 10μL compound solution (final DMSO concentration does not exceed 1%), 80μL of the above protein solution and 10μL [ 3 [H]-cAMP (final concentration 0.005 μCi / μL). After incubation at 30°C for 10 minutes, the reaction was terminated by adding 25 μL of phosphodiesterase SPA scintillation beads. The mixture was allowed to stand at room temperature for 20 minutes, and luminescence was measured using a MicroBeta 2 liquid scintillation counter. All experimental data were analyzed using GraphPad Prism version 8.0 (GraphPad Inc.). The results are shown in Table 2.

[0190] Table 2. Inhibition rate of PDE4 by different concentrations of compounds Description: N / A: No inhibition; *: 1-25%; **: 26-50%; ***: 51-75%; ****: 76-100%

[0191] As can be seen from the table above, except for compounds 7a-2, 8a, 9a, 12a, and 18, the other compounds all had significant inhibitory activity against PDE4 at a concentration of 10 μM; at a concentration of 1 μM, compounds 6a, 6b, 7b, 13, 15, and 7b-1 still had significant inhibitory activity against PDE4; and then a concentration-dependent activity test was carried out on the inhibitory activity of compound 7b-1 against PDE4. The results are shown in Figure 1, and it was found that compound 7b-1 had the strongest PDE4 inhibitory activity (IC 50 =0.19 μM), and was superior to the positive compound crisaborole (IC 50 =0.49 μM).

[0192] Test Example 2: Determination of the inhibitory activity of compound 7b-1 on TNF-α secretion in PBMC

[0193] The experiments used an enzyme-linked immunosorbent assay (ELISA) to test the compound's inhibitory activity against the secretion of the inflammatory cytokine TNF-α in human peripheral blood mononuclear cells (hPBMCs). Compound 7b-1's inhibitory activity against PDE4 at the cellular level was evaluated by measuring its inhibitory activity against TNF-α production in an hPBMC inflammatory cell model.

[0194] Specific experimental steps: hPBMC cells were recovered in a 37°C water bath and centrifuged to collect the cell pellet. 6 / mL was resuspended in RPMI1640 medium containing 10% FBS, added to a 96-well plate at 150μL / well, and incubated in a 37°C, 5% CO2 incubator for 2-3 hours. 25μL of gradient concentration compound solution or cell culture medium was added to each well, ensuring that the final concentration of DMSO in each well did not exceed 0.2%, and continued to incubate in a 37°C, 5% CO2 incubator for 1-1.5 hours. Finally, 25μL of LPS (final concentration of 1μg / mL) or cell culture medium was added and incubated at 37°C, 5% CO2 for 24 hours to stimulate the cells to produce TNF-α. The cell supernatant was collected and the inhibitory activity of the compound on TNF-α release was determined using an ELISA kit. The experimental data were analyzed using GraphPad Prism version 8.0 (GraphPad Inc.). The results are shown in Figure 2. The EC of compound 7b-1 for the inhibitory activity of TNF-α production in the hPBMC inflammatory cell model 50The value is 0.32μM.

[0195] Test Example 3: Therapeutic effect of compound 7b-1 on imiquimod-induced psoriasis in mice

[0196] A psoriasis model was established by applying imiquimod to the back skin of female BALB / c mice. The mouse model was scored according to the Psoriasis Area and Severity Index (PASI). The mice were randomly divided into 5 groups of 8 (normal group, model group, low-dose group, and high-dose group). Before the experiment, 100 μL of blood was collected from each animal and centrifuged twice at 4000 g at 4°C to obtain serum. On days 1-5, after depilation, the mice were treated with imiquimod (60 mg per day) applied to the back skin to establish the model. The application was performed once daily. On days 6-15, drug application was initiated. The application method (calculated based on 10 days of treatment) was as follows: Imiquimod was applied around 9:00 am every day, and the remaining imiquimod on the back was wiped off around 3:00 pm. The treatment drug (model group, low-dose group: 0.3% compound 7b-1, high-dose group: 2% compound 7b-1, both 60 mg per day) was then applied.

[0197] From the beginning of modeling to the end of the experiment, the skin on the back of the animals was photographed every morning, and the mouse model was scored and recorded according to the Psoriasis Area and Severity Index (PASI):

[0198] ① Erythema. 0 points means no erythema, 1 point means light red erythema, 2 points means red erythema, 3 points means dark red erythema, and 4 points means very dark erythema;

[0199] ② Scale. 0 means no scales on the surface; 1 means scales are partially covered on the surface of the lesion; 2 means most of the lesion is covered with scales; 3 means almost all of the lesion is covered with scales in layers; 4 means the entire lesion is covered with scales;

[0200] ③ Thickness: 0 points: the lesion is flush with the normal skin; 1 point: the lesion is slightly higher than the normal skin surface; 2 points: the lesion is moderately raised; 3 points: the lesion is thickened and obviously raised; 4 points: the lesion is highly thickened and obviously raised.

[0201] On day 15, 10 days after treatment, 100 μL of blood was collected from each animal and centrifuged twice at 40,000 g to obtain serum. The mice were then euthanized and the back skin (modeling and drug administration sites) was collected and preserved in 4% paraformaldehyde.

[0202] The experimental results are shown in Figure 3. Compared with the model group, the skin lesions in the high-dose group were alleviated in terms of scales, erythema and PASI score starting from the 5th day (P<0.05); the skin lesions in the low-dose group were alleviated in terms of scales and PASI score starting from the 6th day (P<0.05).

[0203] Test Example 4: Therapeutic effect of compound 7b-1 on 2,4-dinitrochlorobenzene (DNCB)-induced atopic dermatitis in mice

[0204] The effect of compound 7b-1 on DNCB-induced atopic dermatitis in mice was tested. Female Balb / C mice were randomly divided into four groups: a blank group, a model group, a 0.3% 7b-1 group, and a positive drug group (containing 2% crisaborole). The mice were depilated before the experiment. On day 1, 5% DNCB was applied to the back skin of the mice to induce sensitization. From days 2 to 8, the mice were treated with drugs (positive drug: 2% crisaborole, 7b-1 group: 0.3% 7b-1, both 50 mg per day). On day 9, 1% DNCB was applied to the back skin to induce an allergic reaction. The mice were observed for 54 hours after the allergic reaction and the severity of dermatitis was assessed. As shown in Table 3, the four categories of symptoms on the back skin of mice (erythema or hemorrhage, edema or papules, scales or dryness, and epidermal exfoliation or scratches) were evaluated, with scores of 0 (none), 1 (mild), 2 (moderate), and 3 (severe). Dermatitis symptoms between the two degrees were scored as 0.5 points. The final score of mouse back dermatitis was the sum of the four categories of symptoms.

[0205] Table 3. Atopic dermatitis lesion scoring table

[0206] The experimental results are shown in FIG4 . Compared with the model group, 7b-1 showed significant differences in skin lesion and scale scores (P<0.001), which were comparable to those of the positive drug crisaborole group.

[0207] Test Example 5: Skin Sensitivity Improvement Function Test

[0208] Apply 50 μL of 10% (w / w) lactic acid aqueous solution to the nasolabial groove on either side, and apply normal saline to the other side. Ask the subject about their subjective symptoms at 30 seconds, 2.5 minutes, and 5 minutes, and record them. Score according to the 4-point system (0 for no tingling, 1 for mild tingling, 2 for moderate tingling, and 3 for severe tingling). Subtract the total scores of the two sides (10% lactic acid side and normal saline control side). Those with a difference of ≥3 points are considered to have a positive lactic acid tingling reaction. Select subjects with a positive lactic acid tingling reaction as qualified subjects for the next test.

[0209] Sample Testing: Subjects with a positive lactic acid sting reaction were randomly divided into 14 groups (aged 20-50 years, half male and half female), with 5 participants per group. The control group did not use any product, while the experimental group used one of the examples or comparative examples shown in Table 4, once daily. The testing period lasted 28 days, with lactic acid sting tests performed on the first day (D0), fourteenth day (D14), and twenty-eighth day (D28) of the study. Skin hydration was also measured using a skin moisture meter. The results are shown in Tables 4 and 5.

[0210] Table 4 Average scores of lactic acid sting test for subjects in each group

[0211] As shown in Table 4, the lactic acid sting test scores decreased in the test groups for each sample preparation, indicating that the skin sensitivity of the subjects using each sample preparation decreased and the skin barrier was improved. In contrast, the skin sensitivity score did not decrease in the comparative preparation lacking compound 7b, indicating that the lack of compound 7b significantly reduced the repair properties of the lotion.

[0212] Table 5 Average skin moisture content of subjects in each group

[0213] As shown in Table 5, the skin moisture content of the subjects in each preparation example increased, corresponding to the lactic acid stinging score, indicating that the skin barrier function of the subjects in each example improved, the skin condition improved, and the water retention capacity was enhanced. In contrast, the skin sensitivity score of the comparative preparation example without compound 7b did not decrease, indicating that the repair performance of the lotion was significantly reduced in the absence of compound 7b.

[0214] The results in Tables 4 and 5 above demonstrate that cosmetics containing compound 7b can significantly improve skin sensitivity.

[0215] Summarize

[0216] Experiments have shown that the compound of formula I described in the present invention can significantly inhibit PDE4 enzyme activity, increase intracellular cAMP content, and significantly inhibit the secretion of inflammatory factor TNF-α in human peripheral blood mononuclear cells. The IC of representative compound 7b-1 for inhibiting PDE4 at the enzyme level is 50 =0.19μM, 7b-1 inhibits the secretion of inflammatory factor TNF-α in human peripheral blood mononuclear cells at the cellular level. 50 = 0.32 μM. In pharmacodynamic experiments, representative compound 7b-1 effectively reduced skin lesions in mice with imiquimod-induced psoriasis and mice with DNCB-stimulated atopic dermatitis, demonstrating clear therapeutic efficacy for psoriasis and atopic dermatitis. Therefore, compounds of Formula I are promising as active ingredients for the preparation of drugs for the prevention and treatment of phosphodiesterase 4-related diseases, and have broad application prospects in pharmaceuticals and personal care products.

[0217] Finally, it is necessary to explain here that the above embodiments are only used to further illustrate the technical solution of the present invention in detail and cannot be understood as limiting the scope of protection of the present invention. Some non-essential improvements and adjustments made by technicians in this field based on the above content of the present invention all fall within the scope of protection of the present invention.

Claims

1. A compound represented by the following formula I, its stereoisomer, precursor compound, deuterated substance, or pharmaceutically acceptable ester: In formula I, Z is O, NH or S; R1 is selected from H, unsubstituted or halogen-substituted C1-C6 alkyl, unsubstituted or halogen-substituted C3-C6 cycloalkyl, unsubstituted or halogen-substituted benzyl; R2 and R3 are each independently selected from unsubstituted or halogen-substituted C1-C6 alkyl, unsubstituted or halogen-substituted C3-C6 cycloalkyl, and unsubstituted or halogen-substituted benzyl; One of R6 and R7 is H, and the other is in, represents a single bond or a double bond; R4 and R5 are each independently selected from R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl, In the above substituent options Indicates the key connection position, Provided that the compound of formula I does not include compound 2. The compound of formula I according to claim 1, its stereoisomer, precursor compound, deuterated substance, or pharmaceutically acceptable ester, which has the structure shown in the following formula I-1: In formula I-1, each substituent is as defined in claim 1.

3. A compound of formula I according to claim 1, its stereoisomer, precursor compound, deuterated substance, or pharmaceutically acceptable ester, in, In Formula I, Z is O; R1 is selected from H, C1-C6 alkyl; R2 and R3 are each independently C1-C6 alkyl; R6 is H, and R7 is Or R6 is and R7 is H, wherein, represents a single bond or a double bond; R4 and R5 are each independently selected from R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl, In the above substituent options Indicates the key connection location.

4. A compound of formula I according to claim 1, a stereoisomer, a precursor compound, a deuterated substance, or a pharmaceutically acceptable ester thereof, in, In Formula I, Z is O; R1 is H or methyl; R2 and R3 are both methyl, or R2 and R3 are both ethyl; R6 is H, and R7 is Or R7 is H, and R6 is in, represents a single bond or a double bond; R4 and R5 are each independently selected from R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl, In the above substituent options Indicates the key connection location.

5. A compound selected from the following structures:

6. A pharmaceutical composition comprising a compound of formula I as claimed in any one of claims 1 to 5, a deuterated substance thereof, or a pharmaceutically acceptable ester, and a pharmaceutically acceptable excipient.

7. Use of a compound of formula I, a deuterated substance thereof, or a pharmaceutically acceptable ester thereof, or a pharmaceutical composition comprising the same, in the preparation of a medicament for treating a disease mediated by upregulation of phosphodiesterase 4, a PDE4 inhibitor, or a cosmetic for improving skin sensitivity: In formula I, Z is O, NH or S; R1 is selected from H, unsubstituted or halogen-substituted C1-C6 alkyl, unsubstituted or halogen-substituted C3-C6 cycloalkyl, unsubstituted or halogen-substituted benzyl; R2 and R3 are each independently selected from unsubstituted or halogen-substituted C1-C6 alkyl, unsubstituted or halogen-substituted C3-C6 cycloalkyl, and unsubstituted or halogen-substituted benzyl; One of R6 and R7 is H, and the other is in, represents a single bond or a double bond; R4 and R5 are each independently selected from Wherein, R8 and R9 are each independently selected from H, C1-C6 alkyl or C3-C6 cycloalkyl, R 10 is a C1-C6 alkyl group, In the above substituent options Indicates the key connection location.

8. The use according to claim 7, wherein the compound of formula I is selected from the following:

9. The use according to claim 7 or 8, wherein Such diseases include: diseases involving inflammation, such as asthma, COPD, and pulmonary fibrosis; Allergic disease states, such as atopic dermatitis, urticaria, allergic rhinitis, allergic conjunctivitis, vernal conjunctivitis, eosinophilic granuloma, psoriasis, inflammatory arthritis, rheumatoid arthritis, septic shock, ulcerative colitis, Crohn's disease, chronic glomerulonephritis, endotoxic shock, cystic fibrosis, arterial restenosis, atherosclerosis, keratosis, rheumatoid spondylitis, osteoarthritis, diabetes, pneumoconiosis, toxic and allergic contact eczema, atopic eczema, seborrheic eczema, lichen simplex, pruritus of the anogenital area, alopecia areata, hypertrophic scars, discoid lupus erythematosus, systemic lupus erythematosus, follicular and generalized pyoderma, intrinsic or extrinsic acne, rosacea, Beghet's disease, Henoch-Schönlein purpura nephritis, inflammatory bowel disease, leukemia, multiple sclerosis, gastrointestinal diseases, autoimmune diseases; Cardiovascular diseases, such as arrhythmia, heart failure, idiopathic dilated cardiomyopathy, acute myocardial infarction, myocardial ischemia-reperfusion injury, and ischemic pulmonary hypertension; Neurological and psychiatric disorders, such as Alzheimer's disease, multiple sclerosis, amyotrophic lateral sclerosis (ALS), multiple system atrophy (MSA), schizophrenia, Parkinson's disease, Huntington's disease, Pick's disease, depression, stroke, and spinal cord injury, vascular dementia, fragile X syndrome; and Malignancies, including central nervous system tumors, hematological malignancies, lung cancer, liver cancer, oral cancer, breast cancer, colon cancer, stomach cancer, skin cancer, prostate cancer, head and neck cancer, bladder cancer, and pancreatic cancer.

10. The use according to claim 7 or 8, wherein The disease is psoriasis or atopic dermatitis.

Citation Information

Patent Citations

  • Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs

    US20070123570A1

  • Therapeutic Agent For Phosphodiesterase Inhibition And Its Related Disorders

    US20200022931A1

  • Novel PDE4 inhibitors

    WO2007142929A2

  • The derivatives of 8-epiblechnic acid and their effects on down-regulation of endothelin (ETA) receptor mRNA

    WO2010022049A1

  • Anti-inflammation composition using vladinol f

    WO2013095027A1